NASDAQ : RIGL
Rigel Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 51.45 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 961.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 958.46M |
| Enterprise Value | 903.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 18.68M |
| Shares Outstanding | 18.68M |
| Shares Change (YoY) | +8.67% |
| Shares Change (QoQ) | -0.59% |
| Owned by Insiders (%) | 1.74% |
| Owned by Institutions (%) | 74.69% |
| Float | 14.84M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 3.12 |
| Forward PE | 16.00 |
| PS Ratio | 3.46 |
| Forward PS | 2.88 |
| PB Ratio | 2.25 |
| P/TBV Ratio | 2.89 |
| P/FCF Ratio | 12.07 |
| P/OCF Ratio | 12.07 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 2.81 |
| EV / Sales | 3.26 |
| EV / EBITDA | 10.07 |
| EV / EBIT | 10.37 |
| EV / FCF | 11.38 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.94 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.44 |
| Debt / FCF | 0.50 |
| Interest Coverage | 15.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 126.90% |
| Return on Assets (ROA) | 14.95% |
| Return on Invested Capital (ROIC) | 26.03% |
| Return on Capital Employed (ROCE) | 20.46% |
| Weighted Average Cost of Capital (WACC) | 10.81% |
| Revenue Per Employee | $1.59M |
| Profits Per Employee | $1.85M |
| Employee Count | 174 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 3.38 |
Taxes
| Measure | Value |
|---|
| Income Tax | -236.33M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +74.52% |
| 50-Day Moving Average | 47.69 |
| 200-Day Moving Average | 37.15 |
| Relative Strength Index (RSI) | 64.38 |
| Average Volume (20 Days) | 206,559 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.73M |
| Short Previous Month | 2.86M |
| Short % of Shares Out | 14.63% |
| Short % of Float | 18.41% |
| Short Ratio (days to cover) | 11.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 276.79M |
| Gross Profit | 209.27M |
| Operating Income | 87.05M |
| Pretax Income | 85.58M |
| Net Income | 321.91M |
| EBITDA | 89.70M |
| EBIT | 87.05M |
| Earnings Per Share (EPS) | $16.45 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 95.33M |
| Total Debt | 39.95M |
| Net Cash | 55.38M |
| Net Cash Per Share | $2.96 |
| Equity (Book Value) | 425.42M |
| Book Value Per Share | 22.81 |
| Working Capital | 89.94M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 79.39M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.65M |
| Net Borrowing | -22.75M |
| Free Cash Flow | 79.39M |
| FCF Per Share | $4.25 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.61% |
| Operating Margin | 31.45% |
| Pretax Margin | 30.92% |
| Profit Margin | 116.30% |
| EBITDA Margin | 32.41% |
| EBIT Margin | 31.45% |
| FCF Margin | 28.68% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.67% |
| Shareholder Yield | -8.67% |
| Earnings Yield | 32.06% |
| FCF Yield | 8.28% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $63.00 |
| Price Target Difference | 22.78% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 14.76% |
| EPS Growth Forecast (3Y) | -1.30% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 27, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.38 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |